

Level 2, 66 Hunter Street
Sydney NSW 2000
Tel: (61-2) 9300 3344
Fax: (61-2) 9221 6333
E-mail: pnightingale@biotron.com.au
Website: www.biotron.com.au

23 July 2010

The Manager Companies
ASX Limited
20 Bridge Street
Sydney NSW 2000

(1 page by email)

Dear Madam

PRESENTATION AT INTERNATIONAL AIDS CONFERENCE

The Directors of Biotron Limited ('Biotron') are pleased to advise that the latest data on its HIV program was presented to an international audience this week at the XVIII International AIDS Conference in Vienna, Austria.

Dr John Wilkinson, Biotron's Senior Virologist, presented data which showed that Biotron's lead investigational drug, BIT225, has the potential to prevent the establishment of HIV infection in the first cells to encounter the virus at the point of infection. These cells, called dendritic cells, act as the 'watch dogs' of the immune system, so reach the virus first when it gets into the body. Within approximately 24 hours of first infection, HIV starts replicating in these dendritic cells, and is then transmitted to the body's T cells, where the virus establishes a more explosive infection.

Delegates at the conference heard that BIT225 was able to significantly reduce levels of HIV in dendritic cells in the laboratory, with up to 89% reduction in virus transferred to uninfected T cells.

The results are significant as prevention or minimisation of the establishment of HIV infection would potentially ameliorate the devastating effects of HIV infection in the body. The finding opens up a new avenue for potential exploitation of BIT225, in addition to its potential use in controlling viral reservoirs in patients with established infection.

Biotron is now progressing protocols for a Phase Ib/IIa trial of BIT225 in HIV patients. This trial is in addition to the proposed Phase II trial of the same drug in patients infected with Hepatitis C virus (HCV).

For further information please contact Dr Michelle Miller, Managing Director, on (61-2) 9805 0488.

Yours sincerely



Peter J. Nightingale
Company Secretary

pjn5469